• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Bristol Myers CEO sees mid-decade transition, late decade growth

cafead

Administrator
Staff member
  • cafead   Feb 04, 2024 at 12:42: PM
via Bristol Myers Squibb's (BMY.N), new chief executive said on Friday that the company was focused on driving growth toward the end of the decade but would first need to weather a difficult transition period beginning in 2026.

article source